- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Bryostatin-1 belongs to the family of macrocyclic lactones isolated from the marine bryozoan Bugula neritina and is a potent activator of protein kinase C (PKC). Bryostatin has been
demonstrated to possess both in vivo and in vitro anti-leukaemic potential. In samples derived from chronic myeloid leukaemia (CML) patients, it has been demonstrated that bryostatin-1
induces a macrophage differentiation, suppresses colony growth in vitro and promotes cytokine secretion from accessory cells. We investigated the effect of bryostatin-1 treatment on
colony-forming unit–granulocyte macrophage (CFU–GM) capacity in the presence of accessory cells, using mononuclear cells, as well as in the absence of accessory cells using purified
CD34-positive cells. Cells were obtained from 14 CML patients as well as from nine controls. Moreover, CD34-positive cells derived from CML samples and controls were analysed for stem cell
frequency and ability using the long-term culture initiating cell (LTCIC) assay at limiting dilution. Individual colonies derived from both the CFU–GM and LTCIC assays were analysed for the
presence of the bcr–abl gene with fluorescence in situ hybridization (FISH) to evaluate inhibition of malignant colony growth.
The results show that at the CFU–GM level bryostatin-1 treatment resulted in only a 1.4-fold higher reduction of CML colony growth as compared to the control samples, both in the presence
and in the absence of accessory cells. However, at the LTCIC level a sixfold higher reduction of CML growth was observed as compared to the control samples. Analysis of the LTCICs at
limiting dilution indicates that this purging effect is caused by a decrease in output per malignant LTCIC combined with an increase in the normal stem cell frequency. It is concluded that
bryostatin-1 selectively inhibits CML growth at the LTCIC level and should be explored as a purging modality in CML.
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Arnoldus, E. P., Wiegant, J., Noordermeer, I. A., Wessels, J. W., Beverstock, G. C., Grosveld, G. C., van der Ploeg, M. & Raap, A. K. (1990). Detection of the Philadelphia chromosome in
interphase nuclei. Cytogen Cell Genet 54: 108–111.
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Anyone you share the following link with will be able to read this content: